UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tau-targeting therapies for Alzheimer disease

Nature reviews. Neurology, 2018-07, Vol.14 (7), p.399-415

2018

Volltextzugriff (PDF)

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

The Journal of neuroscience, 2010-12, Vol.30 (49), p.16559-16566

2010

Volltextzugriff (PDF)

Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

Journal of neurochemistry, 2011-08, Vol.118 (4), p.658-667

2011

Volltextzugriff (PDF)

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls

Journal of Alzheimer's disease, 2018-01, Vol.66 (2), p.855-856

Sigurdsson, Einar M.

2018

Volltextzugriff (PDF)

Tau Immunotherapy

Neuro-degenerative diseases, 2016-01, Vol.16 (1-2), p.34-38

Sigurdsson, Einar M.

2016

Volltextzugriff (PDF)

Tau immunotherapy for Alzheimer's disease

Trends in molecular medicine, 2015-06, Vol.21 (6), p.394-402

2015

Volltextzugriff (PDF)

Current Status of Clinical Trials on Tau Immunotherapies

Drugs (New York, N.Y.), 2021-07, Vol.81 (10), p.1135-1152

2021

Volltextzugriff (PDF)

Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models

Neurobiology of disease, 2020-04, Vol.137, p.104770-104770, Article 104770

2020

Volltextzugriff (PDF)

Histological staining of amyloid and pre-amyloid peptides and proteins in mouse tissue

Methods in molecular biology (Clifton, N.J.), 2012, Vol.849, p.411

2012

Volltextzugriff (PDF)

Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls

Journal of Alzheimer's disease, 2018, Vol.64 (s1), p.S555

Sigurdsson, Einar M

2018

Volltextzugriff (PDF)

Anti-tau single domain antibodies clear pathological tau and attenuate its toxicity and related functional defects

Cell death & disease, 2024-07, Vol.15 (7), p.543-14, Article 543

2024

Volltextzugriff (PDF)

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies

Journal of Alzheimer's disease, 2024-02, p.1-12

Sigurdsson, Einar M.

2024

Volltextzugriff (PDF)

Single-domain antibody-based protein degrader for synucleinopathies

Molecular neurodegeneration, 2024-05, Vol.19 (1), p.44-24, Article 44

2024

Volltextzugriff (PDF)

Increased neuronal activity in motor cortex reveals prominent calcium dyshomeostasis in tauopathy mice

Neurobiology of disease, 2021-01, Vol.147, p.105165-105165, Article 105165

2021

Volltextzugriff (PDF)

Dynamics of Internalization and Intracellular Interaction of Tau Antibodies and Human Pathological Tau Protein in a Human Neuron-Like Model

Frontiers in neurology, 2020-11, Vol.11, p.602292-602292

2020

Volltextzugriff (PDF)

Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging

EBioMedicine, 2018-09, Vol.35, p.270-278

2018

Volltextzugriff (PDF)

Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

EBioMedicine, 2022-10, Vol.84, p.104249, Article 104249

2022

Volltextzugriff (PDF)

Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model

Frontiers in aging neuroscience, 2020-01, Vol.11, p.377-377

2020

Volltextzugriff (PDF)

Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging

Journal of neuroscience research, 2008-09, Vol.86 (12), p.2784-2791

2008

Volltextzugriff (PDF)

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

The Journal of biological chemistry, 2013-11, Vol.288 (46), p.33081-33095

2013

Volltextzugriff (PDF)

Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model

Frontiers in psychiatry, 2011, Vol.2, p.59-59

2011

Volltextzugriff (PDF)

Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments

Acta neuropathologica communications, 2013-07, Vol.1 (1), p.34-34, Article 34

2013

Volltextzugriff (PDF)

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau

Frontiers in nuclear medicine, 2023, Vol.3

2023

Volltextzugriff (PDF)

Tau-targeting therapies for Alzheimer disease: current status and future directions

Nature reviews. Neurology, 2023-12, Vol.19 (12), p.715-736

2023

Volltextzugriff (PDF)

Response: Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model

Frontiers in aging neuroscience, 2020-07, Vol.12, p.205-205

2020

Volltextzugriff (PDF)

1 – 25 von 247

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(148)

Publikationsform

Sprache

Englisch
(247)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tau-targeting therapies for Alzheimer disease

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls

Tau Immunotherapy

Tau immunotherapy for Alzheimer's disease

Current Status of Clinical Trials on Tau Immunotherapies

Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models

Histological staining of amyloid and pre-amyloid peptides and proteins in mouse tissue

Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls

Anti-tau single domain antibodies clear pathological tau and attenuate its toxicity and related functional defects

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies

Single-domain antibody-based protein degrader for synucleinopathies

Increased neuronal activity in motor cortex reveals prominent calcium dyshomeostasis in tauopathy mice

Dynamics of Internalization and Intracellular Interaction of Tau Antibodies and Human Pathological Tau Protein in a Human Neuron-Like Model

Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging

Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model

Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model

Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau

Tau-targeting therapies for Alzheimer disease: current status and future directions

Response: Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model

Suchergebnisse filtern